Resistant Hypertension Course Scientific Board’s view on Medtronic’s press release about SYMPLICITY HTN-3

In light of Medtronic’s announcement of Thursday, 9th January 2014, about SYMPLICITY HTN-3, the Resistant Hypertension Course Scientific Board shares its point of view.

Medtronic, Inc. announced yesterday that its U.S. trial in renal denervation for treatment-resistant hypertension, SYMPLICITY HTN-3, has met its primary safety endpoint, while it did not reach its primary efficacy endpoint, defined as a difference of, at least, 15 mmHg office systolic blood pressure, between sham and active renal denervation groups.

The RHC Board shares its point of view:

Exclusive interview with Thomas Zeller

 Thomas Zeller (Germany) answers the following questions :

- Why come to RHC 2014 in Berlin, next February?

- Why is a pharmacology-oriented session important for the participants?

 

My patient presents with "uncontrolled hypertension": how to screen for secondary causes and optimise drug treatment

RHC Asia-Pacific 2013 - Discover the new presentations from the second session.

In these 3 case-based presentations you can learn how to:

- conduct a personalised, step-by-step assessment of a patient presenting with "uncontrolled hypertension"

- better understand what information is key to conclude for  resistant hypertension of secondary causes

- optimise the combinations of antihypertensive drugs before concluding to "resistant essential hypertension"

Pages